EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hydroxyurea Uptake in Paediatric Sickle Cell Anaemia: A Seven-Year Quantitative Evaluation at the Jos University Teaching Hospital, Jos, Nigeria

Akinyemi O.D. Ofakunrin, Ruth O. Adah, Patience U. Kanhu, Oluwaseyi T. Adeoti, Pannan J. Yangshwa, Ijeoma N. Diaku-Akinwumi, Olukemi O. Ige, Edache S. Okpe, Stephen Oguche

Highland Medical Research Journal · 23.01.2026 · 24 (2) · 26-31

DOI: 10.4314/hmrj.v24i2.5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Highland Medical Research Journal, online erschienen am 23.01.2026. Verfasst von Akinyemi O.D. Ofakunrin und 8 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sickle cell anaemia (SCA) imposes a significant disease burden in sub-Saharan Africa, with Nigeria bearing the highest national prevalence worldwide. Although international guidelines recommend early initiation of hydroxyurea (HU) in paediatric SCA, uptake remains low in many low- and middle-income settings due to limited provider knowledge, cost constraints, and supply challenges.

Methods

We conducted a retrospective, descriptive crosssectional study of 517 children aged 1–17 years with confirmed SCA who commenced HU therapy at Jos University Teaching Hospital (JUTH), Nigeria, between 2016 and 2023. Using a dedicated Sickle Cell Disease registry, we extracted data on demographics, HU initiation age, treatment duration and dose, clinical indications, and initiation motivations. Uptake trends were assessed by the proportion of HU recipients relative to the total paediatric SCD population.

Results

HU was initiated between the ages of 1 and 5 years in 40.2% of the patients, with the youngest starting at 12 months. The cohort comprised 53.8% males. Frequent vaso-occlusive crises were the most common indication for HU initiation (59.8%), while patient or caregiver testimonials motivated 62.0% of participants to begin therapy. HU uptake increased markedly from 1.2% in 2016 to 44.3% in 2023—a more than forty-fold rise. The mean HU duration was 57.2 months, and the mean dose was 21.8 mg/kg/day.

Conclusion

Despite systemic barriers, JUTH successfully implemented and scaled HU therapy for paediatric SCA. Key enablers included focused physician training, community engagement via patient and caregiver success stories, and targeted policy support—including NIH-funded medication provision during the pilot phase.

Zitieren

APA

Ofakunrin, A. O., Adah, R. O., Kanhu, P. U., Adeoti, O. T., Yangshwa, P. J., Diaku-Akinwumi, I. N., Ige, O. O., Okpe, E. S., & Oguche, S. (2026). Hydroxyurea Uptake in Paediatric Sickle Cell Anaemia: A Seven-Year Quantitative Evaluation at the Jos University Teaching Hospital, Jos, Nigeria. Highland Medical Research Journal, 24(2), 26-31. https://doi.org/10.4314/hmrj.v24i2.5

Vancouver

Ofakunrin AO, Adah RO, Kanhu PU, Adeoti OT, Yangshwa PJ, Diaku-Akinwumi IN, et al. Hydroxyurea Uptake in Paediatric Sickle Cell Anaemia: A Seven-Year Quantitative Evaluation at the Jos University Teaching Hospital, Jos, Nigeria. Highland Medical Research Journal. 2026;24(2):26-31. doi:10.4314/hmrj.v24i2.5

BibTeX
@article{Ofakunrin2026,
  author = {Ofakunrin, Akinyemi O.D. and Adah, Ruth O. and Kanhu, Patience U. and Adeoti, Oluwaseyi T. and Yangshwa, Pannan J. and Diaku-Akinwumi, Ijeoma N. and Ige, Olukemi O. and Okpe, Edache S. and Oguche, Stephen},
  title = {Hydroxyurea Uptake in Paediatric Sickle Cell Anaemia: A Seven-Year Quantitative Evaluation at the Jos University Teaching Hospital, Jos, Nigeria},
  journal = {Highland Medical Research Journal},
  year = {2026},
  volume = {24},
  number = {2},
  pages = {26--31},
  doi = {10.4314/hmrj.v24i2.5}
}
Kostenlos starten →